Vaxcyte’s VAX-31 Phase 3 results are in, and they are among the most closely watched vaccine readouts of the year. On October 5, 2026, Vaxcyte, Inc. (NASDAQ: PCVX) reported that its 31-valent pneumococcal conjugate vaccine candidate, VAX-31, met all of its prespecified primary endpoints in OPUS-1, the pivotal adult Phase 3 trial that compared it head-to-head with the two newest pneumococcal vaccines on the U.S. market. Below, we explain the science in plain language, what the data do and do not show, who could eventually benefit, and what has to happen before the vaccine could reach a pharmacy.
Key Takeaways
- What happened: Vaxcyte announced topline data from OPUS-1, a randomized, double-blind Phase 3 trial of VAX-31 in 4,047 U.S. adults (company press release).
- Headline result: VAX-31 met noninferiority on all 20 serotypes it shares with Pfizer’s Prevnar 20 (PCV20) and on 17 of 19 shared serotypes versus Merck’s Capvaxive (PCV21), and it met superiority criteria on its three unique serotypes plus a cross-reactive serotype, 20B.
- Safety: The company reported a safety profile similar to the comparator vaccines, with no vaccine-related serious adverse events.
- Next steps: Two more Phase 3 trials (OPUS-2 and OPUS-3) are expected to read out in the first half of 2027, and Vaxcyte plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2028.
- Important caveat: These are immune-response (antibody) results, not data showing fewer infections. VAX-31 is an investigational vaccine and is not approved anywhere.
The Science in Plain Language: What Is a 31-Valent Pneumococcal Vaccine?
Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae. It can cause ear and sinus infections, but it can also cause pneumonia, bloodstream infections and meningitis. According to the U.S. Centers for Disease Control and Prevention (CDC), invasive disease, in which the bacteria spread to normally sterile parts of the body such as the blood, is usually very serious and can be fatal. Older adults face the greatest risk of serious complications.
There are roughly 100 known “serotypes” of the bacterium, each distinguished by the sugar coating (polysaccharide capsule) on its surface. A conjugate vaccine links those sugars to a carrier protein so the immune system mounts a stronger, longer-lasting response. The number in a vaccine’s name, such as PCV20 or PCV21, is the number of serotypes it targets. VAX-31 targets 31.
The engineering challenge is that adding more serotypes to one shot has historically risked weakening the immune response to some of them, a problem sometimes called carrier-induced suppression. Vaxcyte says its cell-free protein synthesis platform is designed to address that challenge. That is a company statement about its technology; the OPUS-1 data are the first pivotal test of whether broader coverage can be achieved without giving up response strength.
Today’s adult options
The CDC currently recommends pneumococcal vaccination for all adults aged 50 and older and for adults aged 19 to 49 with certain risk conditions. Available conjugate vaccines include PCV15, PCV20 (Prevnar 20, Pfizer, NYSE: PFE) and PCV21 (Capvaxive, Merck, NYSE: MRK). Because PCV20 and PCV21 cover different sets of serotypes, Vaxcyte argues that adults currently face a trade-off that a single 31-valent shot could remove.
VAX-31 Phase 3 Results: What OPUS-1 Measured and Found
Trial design (verified facts from the company’s release)
| Feature | OPUS-1 detail |
|---|---|
| Design | Randomized, double-blind, active-controlled Phase 3 |
| Participants | 4,047 adults at about 30 U.S. sites |
| Adults 50+ | 3,572 participants randomized 1:1:1 to VAX-31, PCV20 or PCV21 |
| Adults 18–49 | 475 participants randomized 3:1 to VAX-31 or PCV20 |
| Main measure | Opsonophagocytic activity (OPA) antibody titers, a lab measure of how well antibodies help immune cells kill the bacteria |
| Noninferiority test | Lower bound of the 95% confidence interval of the geometric mean ratio above 0.667 |
| Superiority test (unique serotypes) | Lower bound of the confidence interval above 2.0 |
Results by comparison
| Comparison | Result reported by Vaxcyte |
|---|---|
| VAX-31 vs. PCV20 (shared serotypes) | 20 of 20 met noninferiority |
| VAX-31 vs. PCV21 (shared serotypes) | 17 of 19 met the 0.667 noninferiority threshold; serotypes 3 and 12F missed it but met a historical 0.5 threshold |
| Three serotypes unique to VAX-31, plus cross-reactive 20B | Met superiority criteria |
| Adults 18–49 (immunobridging vs. adults 50–64) | Met noninferiority |
| Safety | Profile similar to comparators; no vaccine-related serious adverse events; no discontinuations due to adverse events; local and systemic reactions mostly mild to moderate and generally resolved within 48 hours |
Vaxcyte says it met all prespecified primary endpoints, which included the stricter and historical thresholds described in its release. Readers should note that the serotype 3 and 12F results versus PCV21 fell short of the stricter 0.667 cutoff; how regulators weigh that will become clearer during review.
Coverage estimates
Vaxcyte estimates that, for adults 50 and older, VAX-31 would provide 13% to 36% incremental coverage of invasive pneumococcal disease compared with currently available conjugate vaccines (based on CDC Active Bacterial Core surveillance data for 2022–2024) and 19% to 31% incremental coverage of pneumococcal pneumonia (based on a 2025 study in the Journal of Infectious Diseases). These are company estimates of serotype coverage, not measured reductions in disease.
Who Could VAX-31 Help?
- Adults 50 and older, the group in which OPUS-1 tested superiority and noninferiority and which is already covered by CDC vaccination recommendations.
- Younger adults with risk conditions, for whom the 18–49 immunobridging cohort is relevant.
- Infants and children are a separate question. Vaxcyte says a Phase 2 infant dose-finding study is ongoing, with primary-series and booster data expected around the end of the first half of 2027. The adult OPUS-1 data do not establish anything about infant use.
Company Statements vs. Independent Context
What the company says
In its release, Vaxcyte’s leadership described the results as supporting VAX-31’s potential to provide broader protection against invasive pneumococcal disease, and its chief medical officer, Luis Jodar, said that today’s adult vaccines differ in the serotypes they cover, requiring trade-offs (as reported by pharmaphorum).
Market reaction (verified)
Vaxcyte shares rose roughly a third on October 5 following the announcement, according to pharmaphorum and GuruFocus. Pharmaphorum also reported that Pfizer’s Prevnar franchise generated about $3 billion in the first half of 2026 and Capvaxive about $325 million, illustrating the size of the market. Vanderbiltreport.com does not provide investment recommendations.
Analysis: what the data cannot yet tell us
- Antibodies are a surrogate. Pneumococcal vaccines are routinely approved on immunogenicity comparisons, but OPA titers are not the same as documented reductions in pneumonia or hospitalizations.
- Topline only. Full data, including detailed safety tables and confidence intervals for each serotype, have not yet been published in a peer-reviewed journal.
- More trials pending. OPUS-2 and OPUS-3 must still read out before a BLA, which is not planned until the first half of 2028.
- Regulatory review. Any approval decision rests with the FDA and, for routine use recommendations, with the CDC’s vaccine advisory process.
What Comes Next for VAX-31
| Milestone | Expected timing (company guidance) |
|---|---|
| OPUS-2 and OPUS-3 Phase 3 adult results | First half of 2027 |
| Infant Phase 2 primary-series and booster data | Around end of first half of 2027 |
| BLA submission to the FDA (adults) | First half of 2028 |
Developing information: These timelines are forward-looking company projections and could change. Vaxcyte’s release includes standard cautionary language about clinical, regulatory, manufacturing and funding risks.
Related Coverage on Vanderbiltreport.com
- FDA Approves Emcitate, the First MCT8 Deficiency Treatment
- FDA Panel Backs GRAIL’s Galleri Multi-Cancer Early Detection Test
- Viking Therapeutics’ VK2735 Maintenance Data
Sources
- Vaxcyte press release, October 5, 2026 (GlobeNewswire)
- CDC: Pneumococcal Vaccination
- pharmaphorum: Vaxcyte’s pneumococcal jab exceeds expectations
- GuruFocus: Vaxcyte shares jump on Phase 3 results
This article is for general information only and is not medical advice. Questions about pneumococcal vaccination should be directed to a doctor, pharmacist or other healthcare professional.
Publisher Disclaimer: Vanderbiltreport.com publishes news and information for general informational and educational purposes. Information is compiled from sources believed to be reliable, but Vanderbiltreport.com does not guarantee the accuracy, completeness, or timeliness of all information presented. Readers should independently verify information and conduct their own research before making financial, investment, business, or other decisions.
